Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 2/20 | 0.49 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.47 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.44 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.43 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1797592 | 0.98 | CHRNB4 (0.50) | CHRNB4CHRNA3CHRM3SLC6A9CARM1 | |
| SCHEMBL6819282 | 0.98 | CHRNB4 (0.50) | CHRNB4CHRNA3CHRM3SLC6A9CARM1 | |
| SCHEMBL1797593 | 0.98 | CHRNB4 (0.50) | CHRNB4CHRNA3CHRM3SLC6A9CARM1 | |
| SCHEMBL6648223 | 0.93 | CHRNB4 (0.55) | CHRNB4CHRNA3CHRM3CARM1PRMT6 | |
| SCHEMBL4781411 | 0.89 | CHRNB4 (0.46) | CHRNB4CHRNA3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4725436 | 0.89 | CHRNB4 (0.46) | CHRNB4CHRNA3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4725442 | 0.89 | CHRNB4 (0.46) | CHRNB4CHRNA3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6839407 | 0.84 | SLC6A3 (0.43) | CHRNB4CHRNA3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4780734 | 0.84 | SLC6A2 (0.43) | CHRNB4CHRNA3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4780731 | 0.84 | SLC6A2 (0.43) | CHRNB4CHRNA3SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700585-B2 | Derivatives of N-[phenyl(pyrrolidine-2-YL)methyl]benzamide and N-[(azepan-2-YL) phenylmethyl]benzamide, preparation method thereof and application of same in therapeutics | SANOFI-AVENTIS (FR) | 2010-04-20 | — | — | US | disclosed |
| US-20070208006-A1 | DERIVATIVES OF N-[PHENYL(PYRROLIDINE-2-YL)METHYL]BENZAMIDE AND N-[(AZEPAN-2-YL)PHENYLMETHYL]BENZAMIDE, PREPARATION METHOD THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2007-09-06 | — | — | US | disclosed |
| US-7226917-B2 | Derivatives of N-[phenyl(pyrrolidine-2-yl)methyl]benzamide and N-[(azepan-2-yl)phenylmethyl]benzamide, preparation, and use in treatment of schizophrenia | SANOFI-AVENTIS (FR) | 2007-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208006-A1 | DERIVATIVES OF N-[PHENYL(PYRROLIDINE-2-YL)METHYL]BENZAMIDE AND N-[(AZEPAN-2-YL)PHENYLMETHYL]BENZAMIDE, PREPARATION METHOD THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SNCA, CHRNA10, CHRNA5 | CHRNB4 71/4885CHRNA3 21/4885CHRM3 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.